{Reference Type}: Journal Article
{Title}: A safety review of current monoclonal antibodies used to treat multiple sclerosis.
{Author}: Costa GD;Comi G;
{Journal}: Expert Opin Drug Saf
{Volume}: 22
{Issue}: 11
{Year}: 2023 Jul-Dec 14
{Factor}: 4.011
{DOI}: 10.1080/14740338.2023.2224556
{Abstract}: <B>UNASSIGNED: </B>Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Monoclonal antibodies (mAbs) have shown efficacy in reducing MS relapse rates, disease progression, and brain lesion activity.<BR><B>UNASSIGNED: </B>This article reviews the literature on the use of mAbs for the treatment of MS, including their mechanisms of action, clinical trial data, safety profiles, and long-term outcomes. The review focuses on the three main categories of mAbs used in MS: alemtuzumab, natalizumab, and anti-CD20 drugs. A literature search was conducted using relevant keywords and guidelines and reports from regulatory agencies were reviewed. The search covered studies published from inception to 31 December 202231 December 2022. The article also discusses the potential risks and benefits of these therapies, including their effects on infection rates, malignancies, and vaccination efficacy.<BR><B>UNASSIGNED: </B>Monoclonal antibodies have revolutionized the treatment of MS, but safety concerns must be considered, particularly with regards to infection rates, malignancy risk, and vaccination efficacy. Clinicians must weigh the potential benefits and risks of mAbs on an individual patient basis, taking into account factors such as age, disease severity, and comorbidities. Ongoing monitoring and surveillance are essential to ensure the long-term safety and effectiveness of monoclonal antibody therapies in MS.